Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Zura Bio (NASDAQ:ZURA) issued its quarterly earnings data on Tuesday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), Yahoo Finance reports.

Zura Bio Stock Up 1.5 %

Shares of Zura Bio stock traded up $0.05 on Wednesday, reaching $3.34. The stock had a trading volume of 44,459 shares, compared to its average volume of 280,976. The company has a 50 day moving average price of $3.65 and a 200 day moving average price of $3.76. Zura Bio has a 1 year low of $2.00 and a 1 year high of $7.63.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZURA. Cantor Fitzgerald began coverage on shares of Zura Bio in a research note on Wednesday, June 12th. They issued an “overweight” rating on the stock. Oppenheimer increased their price target on shares of Zura Bio from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Finally, Piper Sandler started coverage on shares of Zura Bio in a research note on Friday, May 3rd. They issued an “overweight” rating and a $26.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zura Bio presently has an average rating of “Buy” and an average price target of $19.75.

Insiders Place Their Bets

In other Zura Bio news, Director Van Amstel Arnout Ploos acquired 80,000 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was acquired at an average cost of $6.20 per share, for a total transaction of $496,000.00. Following the purchase, the director now owns 100,000 shares in the company, valued at approximately $620,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 15.80% of the stock is owned by insiders.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.